frommedchem express Search Results


merestinib frommedchem express  (Selleck Chemicals)
92
Selleck Chemicals merestinib frommedchem express
Figure 4. A and B, Representative snapshot from the MDs trajectory of the com- plex of c-MET and <t>merestinib.</t> Meres- tinib is shown in yellow, interacting amino acids in cyan and the F1200 or I1200 aa residue in green. A, As merestinib binds to WT MET, three phenyl rings from the F1134/F1200/ fluorophenyl tail of merestinib form an aromatic cluster, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interac- tions. B, The F1200I mutation destroys the aromatic cluster, weakening the merestinib–MET interaction. Bottom pane shows protein–ligand interaction histograms for 100 nanoseconds MD simulation of MET F1200I mutant with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. The pro- tein–ligand interaction at I1200 is fully abolished. C and D, Representative snapshot from the MDs trajectory of the complex of MET and capmatinib. Capmatinib is shown in yellow, inter- acting amino acids in cyan and the F1200 or I1200 aa residue in green. C, As capmatinib binds to the WT MET, p–p stacking with Y1230 in the activa- tion loop forms, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with capmatinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. D, Capmatinib keeps an effective p–p stacking interaction with Y1230 in MET F1200I mutant c-Met mutant. Bottom panel shows protein–ligand interaction histograms for 100 nano- seconds MD simulation of MET F1200I with capmatinib. Capmatinib exhibits an efficient binding interac- tion with the mutant. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions.
Merestinib Frommedchem Express, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/frommedchem+express/Merestinib/10__1158_slash_1535___7163__mct___21___0344-47-42-46
Average 92 stars, based on 1 article reviews
merestinib frommedchem express - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
frommedchem express  (MedChemExpress)
91
MedChemExpress frommedchem express
Figure 4. A and B, Representative snapshot from the MDs trajectory of the com- plex of c-MET and <t>merestinib.</t> Meres- tinib is shown in yellow, interacting amino acids in cyan and the F1200 or I1200 aa residue in green. A, As merestinib binds to WT MET, three phenyl rings from the F1134/F1200/ fluorophenyl tail of merestinib form an aromatic cluster, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interac- tions. B, The F1200I mutation destroys the aromatic cluster, weakening the merestinib–MET interaction. Bottom pane shows protein–ligand interaction histograms for 100 nanoseconds MD simulation of MET F1200I mutant with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. The pro- tein–ligand interaction at I1200 is fully abolished. C and D, Representative snapshot from the MDs trajectory of the complex of MET and capmatinib. Capmatinib is shown in yellow, inter- acting amino acids in cyan and the F1200 or I1200 aa residue in green. C, As capmatinib binds to the WT MET, p–p stacking with Y1230 in the activa- tion loop forms, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with capmatinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. D, Capmatinib keeps an effective p–p stacking interaction with Y1230 in MET F1200I mutant c-Met mutant. Bottom panel shows protein–ligand interaction histograms for 100 nano- seconds MD simulation of MET F1200I with capmatinib. Capmatinib exhibits an efficient binding interac- tion with the mutant. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions.
Frommedchem Express, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/frommedchem+express/Columbin/10__1016_slash_j__matpr__2022__12__159-61-3-5
Average 91 stars, based on 1 article reviews
frommedchem express - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier

Image Search Results


Figure 4. A and B, Representative snapshot from the MDs trajectory of the com- plex of c-MET and merestinib. Meres- tinib is shown in yellow, interacting amino acids in cyan and the F1200 or I1200 aa residue in green. A, As merestinib binds to WT MET, three phenyl rings from the F1134/F1200/ fluorophenyl tail of merestinib form an aromatic cluster, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interac- tions. B, The F1200I mutation destroys the aromatic cluster, weakening the merestinib–MET interaction. Bottom pane shows protein–ligand interaction histograms for 100 nanoseconds MD simulation of MET F1200I mutant with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. The pro- tein–ligand interaction at I1200 is fully abolished. C and D, Representative snapshot from the MDs trajectory of the complex of MET and capmatinib. Capmatinib is shown in yellow, inter- acting amino acids in cyan and the F1200 or I1200 aa residue in green. C, As capmatinib binds to the WT MET, p–p stacking with Y1230 in the activa- tion loop forms, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with capmatinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. D, Capmatinib keeps an effective p–p stacking interaction with Y1230 in MET F1200I mutant c-Met mutant. Bottom panel shows protein–ligand interaction histograms for 100 nano- seconds MD simulation of MET F1200I with capmatinib. Capmatinib exhibits an efficient binding interac- tion with the mutant. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions.

Journal: Molecular Cancer Therapeutics

Article Title: Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

doi: 10.1158/1535-7163.mct-21-0344

Figure Lengend Snippet: Figure 4. A and B, Representative snapshot from the MDs trajectory of the com- plex of c-MET and merestinib. Meres- tinib is shown in yellow, interacting amino acids in cyan and the F1200 or I1200 aa residue in green. A, As merestinib binds to WT MET, three phenyl rings from the F1134/F1200/ fluorophenyl tail of merestinib form an aromatic cluster, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interac- tions. B, The F1200I mutation destroys the aromatic cluster, weakening the merestinib–MET interaction. Bottom pane shows protein–ligand interaction histograms for 100 nanoseconds MD simulation of MET F1200I mutant with merestinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. The pro- tein–ligand interaction at I1200 is fully abolished. C and D, Representative snapshot from the MDs trajectory of the complex of MET and capmatinib. Capmatinib is shown in yellow, inter- acting amino acids in cyan and the F1200 or I1200 aa residue in green. C, As capmatinib binds to the WT MET, p–p stacking with Y1230 in the activa- tion loop forms, stabilizing the inter- action. Bottom panel shows protein– ligand interaction histograms for 100 nanoseconds MD simulation of WT MET with capmatinib. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions. D, Capmatinib keeps an effective p–p stacking interaction with Y1230 in MET F1200I mutant c-Met mutant. Bottom panel shows protein–ligand interaction histograms for 100 nano- seconds MD simulation of MET F1200I with capmatinib. Capmatinib exhibits an efficient binding interac- tion with the mutant. Red denotes hydrogen bond interactions and blue denotes hydrophobic interactions.

Article Snippet: Antibodies against phospho-MET (Tyr1234; sc-101736; RRID: AB_2143892) and HSP90 (sc-7947; RRID:AB_2121235) were purchased from Santa Cruz Biotechnology; total-MET (D1C2; No. 8198; RRID:AB_10858224) and anti-rabbit IgG-HRP (No. 7074; RRID: AB_2099233) from Cell Signaling Technology; savolitinib, crizotinib, cabozantinib, and glesatinib were purchased from Selleckchem; merestinib fromMedChem Express and Selleckchem.

Techniques: Residue, Mutagenesis, Binding Assay

Figure 5. The merestinib/capmatinib combination shows efficacy and tolerability in vivo. A, A box plot of volume of tumors harvested from mice on day 18 of treatment. , # denote significance. B, Plot of body weight percent change of treated mice as a function of treatment time. C, The individual contribution of each TPR-MET mutant was determined by ddPCR at the end of the study and expressed as percent tumor volume. Each bar represents an individual treatment subject.

Journal: Molecular Cancer Therapeutics

Article Title: Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

doi: 10.1158/1535-7163.mct-21-0344

Figure Lengend Snippet: Figure 5. The merestinib/capmatinib combination shows efficacy and tolerability in vivo. A, A box plot of volume of tumors harvested from mice on day 18 of treatment. , # denote significance. B, Plot of body weight percent change of treated mice as a function of treatment time. C, The individual contribution of each TPR-MET mutant was determined by ddPCR at the end of the study and expressed as percent tumor volume. Each bar represents an individual treatment subject.

Article Snippet: Antibodies against phospho-MET (Tyr1234; sc-101736; RRID: AB_2143892) and HSP90 (sc-7947; RRID:AB_2121235) were purchased from Santa Cruz Biotechnology; total-MET (D1C2; No. 8198; RRID:AB_10858224) and anti-rabbit IgG-HRP (No. 7074; RRID: AB_2099233) from Cell Signaling Technology; savolitinib, crizotinib, cabozantinib, and glesatinib were purchased from Selleckchem; merestinib fromMedChem Express and Selleckchem.

Techniques: In Vivo, Mutagenesis